短期放疗对比放化疗治疗老年局部晚期直肠癌(UNICANCER PRODIGE 42/GERICO 12研究):生活质量与综合老年评估
PRODIGE 42/GERICO 12研究纳入101例≥75岁可切除T3-T4直肠腺癌患者,随机接受短期放疗(5×5 Gy/1周)或放化疗(50 Gy,2野,卡培他滨800 mg/m²,5天/周),两组均延迟手术(7周±1)。短期放疗组在术后3个月认知功能、疲乏、食欲方面更优,IADL恶化比例更低(14.8% vs 44.8%,p=0.032),GDS15抑郁评分保持更好(p=0.05)。结论:短期放疗在≥75岁局部晚期直肠癌患者中生活质量与自主性保留方面结果更好。
要点
- 短期放疗组术后3个月认知功能、疲乏、食欲优于放化疗组。
- 放化疗组IADL恶化44.8%,短期放疗组14.8%(p=0.032)。
- 短期放疗组GDS15抑郁评分保持更好(p=0.05)。
核心结论
- 短期放疗在≥75岁局部晚期直肠癌患者中生活质量和自主性保留方面结果更好。
研究设计与样本
- PRODIGE 42/GERICO 12研究共纳入101例≥75岁、可切除、距肛缘小于12 cm的T3-T4直肠腺癌患者。
- 患者接受短期放疗(5×5 Gy,1周)或放化疗(50 Gy,2野,卡培他滨800 mg/m²,5天/周),两组均延迟手术(7周±1)。
- 生活质量分析采用EORTC QLQ C-30和ELD14量表,于入组时、术前、术后3、6、12个月进行,同时进行综合老年评估(IADL、ADL、步行速度、GDS15、MMSE、MNA)。
主要发现
- EORTC QLQ-C30总体评分未见统计学差异。
- 术后3个月短期放疗组在认知功能、疲乏、食欲方面有统计学优势。
- ELD14评分显示放化疗组在术后3、6、12个月疾病负担感知更负面。
- IADL评分恶化:放化疗组44.8% vs 短期放疗组14.8%(p=0.032)。
- GDS15抑郁评分在短期放疗组保持更好(p=0.05);ADL、步行速度、MNA、MMSE未见统计学差异。
关键数值与推荐
- 短期放疗方案:5×5 Gy,1周内完成。
- 放化疗方案:50 Gy,2野,卡培他滨800 mg/m²,5天/周。
- 两组均延迟手术7周±1。
- IADL恶化比例:放化疗组44.8% vs 短期放疗组14.8%(p=0.032)。
- GDS15抑郁评分短期放疗组保持更好(p=0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The results of the PRODIGE 42/GERICO 12 study showed that short course radiotherapy had a better tolerance profile than radiochemotherapy, with comparable oncological results. We have included Quality of Life analyses and oncogeriatric evaluations in this study. PATIENTS AND METHODS: In all, 101 patients ≥75 years of age with resectable T3-T4 rectal adenocarcinoma less than 12 cm from the anal margin received short course radiotherapy (5X5 Gy in one week) or radiochemotherapy (50 Gy, 2 y/f and capecitabine 800 mg/m2, 5 days/week) with delayed surgery (7 weeks ± 1) in both groups. The Quality of Life analyses (EORTC QLQ C-30 et ELD14) were conducted upon inclusion, pre-operatively, at 3, 6 and 12 months post-op, together with the oncogeriatric evaluations, including an evaluation of the IADL and ADL scores, walking speed, GDS15, MMSE, MNA. RESULTS: We did not highlight any statistical difference for the global EORTC QLQ-C30 score; several factors are statistically in favor of the short course radiotherapy group at 3 months post-op (cognitive functions, fatigue, appetite). In the case of the ELD14 score, the disease burden is perceived as more negative at 3, 6 and 12 months postop in the radiochemotherapy group. The IADL score deteriorated in 44.8 % of the radiochemotherapy group and 14.8 % of the radiotherapy group (p = 0.032); similarly, the GDS15 depression score was better preserved in the short course radiotherapy group (p = 0.05). An analysis of the other scores: ADL, walking speed, MNA, MMSE did not highlight any statistical difference. CONCLUSION: Short course radiotherapy achieves better results in terms of Quality of Life and preservation of autonomy in patients aged ≥75 treated for locally advanced rectal cancer.
引用
- François E, Magné N, Boulahssass R, et al. Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment. Radiother Oncol. 2024. PMID: 38341097. doi:10.1016/j.radonc.2024.110144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。